An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, with or without BI 754091, in Patients with Stage IV Colorectal Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AMAL Therapeutics S.A.
Start Date
April 28, 2021
End Date
May 20, 2026
Administered By
Duke Cancer Institute
Awarded By
AMAL Therapeutics S.A.
Start Date
April 28, 2021
End Date
May 20, 2026